MedTrace Logo

Study Evaluating the Clinical Remission in Early Aggressive Rheumatoid Arthritis

NCT00267852 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 152

Last updated 2011-09-15

No results posted yet for this study

Summary

This is an observational prospective, multicenter study. The aim of the study is to evaluate how the Italian population of patients are treated with early aggressive RA, defined by the Italian Society of Rheumatology Guidelines, (GIARA Registry Study Group. Clin Exp Rheumatol 2003;21(Suppl. 31):S129-S132), in rheumatologic clinical practice and whether recent scientific evidence or new treatments available to rheumatologists can change their practice in a 2 year follow-up. The observation will primarily focus on the disease activity and clinical remission in patients who are receiving different treatment strategies. The primary goal is to define prevalence of clinical remission, according to the (Disease Activity Score) DAS 28 definition of clinical remission, in patients with early aggressive RA receiving different therapies at 1 year.

Secondary objective are assessment of:

* Prevalence of Remission at the second year
* Disease activity at the first and second year.
* ACR 20%, 50%, 70% response at the first and second year.
* Quality of Life in patients with or without remission at the first and second year
* Safety Evaluations

Conditions

Interventions

OTHER

as clinical practice

Dosage, form, frequency and duration as per ordinary clinical practice

Sponsors & Collaborators

  • Wyeth is now a wholly owned subsidiary of Pfizer

    lead INDUSTRY

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2010-07-31
Completion
2010-07-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00267852 on ClinicalTrials.gov